Efficacy and Safety of 6.25 mg t.i.d. Feverfew CO₂-Extract (MIG-99) in Migraine Prevention — A Randomized, Double-Blind, Multicentre, Placebo-Controlled Study

Abstract

The efficacy and tolerability of a CO(2)-extract of feverfew (MIG-99, 6.25 mg t.i.d.) for migraine prevention were investigated in a randomized, double-blind, placebo-controlled, multicentre, parallel-group study. Patients (N = 170 intention-to-treat; MIG-99, N = 89; placebo, N = 81) suffering from migraine according to International Headache Society criteria were treated for 16 weeks after a 4-week baseline period. The primary endpoint was the average number of migraine attacks per 28 days during the treatment months 2 and 3 compared with baseline. Safety parameters included adverse events, laboratory parameters, vital signs and physical examination. The migraine frequency decreased from 4.76 by 1.9 attacks per month in the MIG-99 group and by 1.3 attacks in the placebo group (P = 0.0456). Logistic regression of responder rates showed an odds ratio of 3.4 in favour of MIG-99 (P = 0.0049). Adverse events possibly related to study medication were 9/107 (8.4%) with MIG-99 and 11/108 (10.2%) with placebo (P = 0.654). MIG-99 is effective and shows a favourable benefit-risk ratio.

Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED]

“…The placebo group reduced migraine frequency by 0.3 attacks/month (baseline ϭ 4.9 Ϯ 0.9 to 4.6 Ϯ 2.2 attacks at week 12; p ϭ 0.02, CI 1.07-2.49). 19 In a second Class II study, described above for magnesium, the efficacy of the combination of magnesium (300 mg), riboflavin (400 mg), and MIG-99 (100 mg) was not shown in comparison with a placebo (25 mg of riboflavin). Omega-3.…”

A Combination of Tanacetum parthenium, Griffonia simplicifolia and Magnesium (Aurastop) as Symptomatic Acute Treatment for Migraine Aura: A Retrospective Cohort Study

“…In the last years, several herbal and/or nutraceutical preparations have been proposed in the management of migraine and related symptoms like aura [13]. In particular: 1) feverfew (Tanacetum parteninum) as potential treatment in reducing aura duration and complexity [14] through Parthenolide inhibition of nitroglycerin-induced neuronal activation in specific brain nuclei, like dorsal root ganglia (DRG) [15]; 2) Griffonia simpliciofila (as a herbal supplement of 5-hydroxytryptophan (5-HTP)); interestingly, 5-HTP could reduce N-methyl-D-Aspartate (NMDA) receptors aberrant activity in trigeminal-vascular system, as well as in CSD developing, principally through…”

Combination of Tanacethum Partenium, 5-Hydrossitriptophan (5-http) and Magnesium in the Prophylaxis of Episodic Migraine without Aura (AURASTOP®) An Observational Study

“…Parthenolide may also interact with TRPA1 nucleophilic sites, suggesting that feverfew antimigraine effect derives from its ability to target TRPA1. TRPA1 partial agonism, together with desensitization and nociceptor defunctionalization, ultimately resulting in inhibition of CGRP release within the trigeminovascular system, may contribute to the antimigraine effect of parthenolide [5][6][7] . Glutamate is another neuropeptide likely involved in migraine pathogenesis.…”